Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 15.09.25 with a price of €2.35. The prediction had a final performance of 23.97%. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 2.657% | 2.657% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21


